Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Next-Generation Cytotoxic Therapy Moves Forward in mCRPC

January 7th 2021

VERU-111, a next-generation form of chemotherapy, has shown promising signs of efficacy as a treatment option for men with metastatic castration-resistant prostate cancer whose disease has progressed while receiving androgen receptor–targeting therapy.

Role for Somatic, Inherited Genetic Testing in Prostate Cancer Continues to Grow

January 3rd 2021

Leonard G. Gomella, MD, discusses the growing importance of genetic testing in prostate cancer.

Practice-Changing Trials Pave the Way for Novel Approaches in Metastatic Prostate Cancer

December 31st 2020

Joseph Kim, MD, discusses pivotal trials in metastatic prostate cancer, the rise of PARP inhibitors and novel combinations under investigation, and the promise of relugolix.

Petrylak Shares Selection Considerations for Available Agents in Hormone-Sensitive Prostate Cancer

December 29th 2020

Daniel P. Petrylak, MD, highlights the use of abiraterone acetate, enzalutamide, and apalutamide and how these agents can lead to improvements in overall survival and progression-free survival in patients with hormone-sensitive prostate cancer.

Antiandrogens Plus ADT Continue to Reign Supreme in Nonmetastatic CRPC

December 28th 2020

Michael E. Hurwitz, MD, PhD, highlights the role of second-generation androgen blockers in nonmetastatic castration-resistant prostate cancer, how these agents compare, and active areas of investigation.

Dr. Schweizer on the Rationale for the CARD Trial in mCRPC

December 21st 2020

Michael Schweizer, MD, discusses the rationale for the phase 3 CARD trial in metastatic castration-resistant prostate cancer.

Dr. Agarwal on Remaining Challenges With Abiraterone in mCSPC

December 21st 2020

Neeraj Agarwal, MD, discusses remaining challenges with abiraterone acetate in metastatic castration-sensitive prostate cancer.

Dr. Shore on the FDA Approval of Relugolix in Advanced Prostate Cancer

December 18th 2020

Neal D. Shore, MD, FACS, discusses the approval of relugolix in advanced prostate cancer.

FDA Approves Relugolix for Advanced Prostate Cancer

December 18th 2020

December 18, 2020 - The FDA has approved the oral gonadotropin-releasing hormone receptor antagonist relugolix as a treatment for patients with advanced prostate cancer.

AR Inhibitors Lead to Higher Fall/Fracture Risk in Older Men With Prostate Cancer

December 17th 2020

December 17, 2020 - Androgen receptor inhibitor–therapy is associated with an increased risk of falls and fractures in patients with prostate cancer. However, since it has shown improvement in overall survival, the benefits may outweigh the risk.

Dr. Hurwitz Compares the Utility of Antiandrogens in Nonmetastatic CRPC

December 16th 2020

Michael E. Hurwitz, MD, PhD, compares the utility of antiandrogens in nonmetastatic castration-resistant prostate cancer.

Sequence of ADT With Radiation Is Crucial for Prostate Cancer Treatment

December 15th 2020

December 15, 2020 — The sequence in which hormonal therapy is given to men with localized prostate cancer should be considered as it can significantly affect outcomes.

Dr. Agarwal on Remaining Challenges in mCSPC

December 11th 2020

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

Gene Expression Testing Varies Substantially by Region for Prostate Cancer

December 10th 2020

December 10, 2020 — Despite gene expression tests helping health care professionals make optimal treatment decisions, testing varies by region for men with prostate cancer and could be related to socioeconomic status and patterns of prostate cancer care.

Standardized Practices Address Challenges With Germline Genetic Testing in Prostate Cancer

December 8th 2020

December 8, 2020 — Although updated guidelines and targeted therapies have led to the routine recommendation of germline genetic testing for patients with prostate cancer, increasing demand for tests and limited access to genetics providers have created an unmet need.

Dr. Schweizer on the Role of Olaparib in Non–BRCA-Mutant mCRPC

December 7th 2020

Michael Schweizer, MD, discusses the role of olaparib in patients with non–BRCA-mutant metastatic castration-resistant prostate cancer.

Oxidative Stress, Antioxidant Status Remain High in Nigerian Patients With Prostate Cancer

December 4th 2020

Nigerian patients with prostate cancer are noted as having higher levels of total plasma peroxide, malondialdehyde, and nitric oxide, as well as lower levels of total antioxidant capacity, even while undergoing androgen-deprivation therapy compared with Nigerian men who don't have prostate cancer.

Dr. Petrylak on the Role of Docetaxel in mHSPC

December 2nd 2020

Daniel P. Petrylak, MD, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Dr. Agarwal on Unmet Needs in mHSPC

December 1st 2020

Neeraj Agarwal, MD, discusses unmet needs in metastatic hormone-sensitive prostate cancer.

FDA Approves Gallium 68 PSMA-11 as PET-Imaging Drug for Prostate Cancer

December 1st 2020

December 1, 2020 - The FDA has approved Gallium 68 PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen–positive lesions in patients with prostate cancer.